ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor (VEGF), under development as an intravitreal injection. Bevacizumab works by ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal faricimab injections, and occlusive retinal vasculitis d ...

The rapid growth in IVT injections has resulted from the introduction ... IVT implant for the treatment of DME. In addition, bevacizumab is commonly used off-label for the treatment of AMD ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

The concern of endophthalmitis is casting a larger spector over the treatment of ocular conditions with intravitreal injection. Bevacizumab is typically obtained through such compounding ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Pegaptanib costs £514 per injection. Whilst bevacizumab does not have a license for ocular use, it is a much less costly alternative. A 4ml vial for its licensed intravenous use costs £242.66.